Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia
Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia
Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia
Submitted by
admin
on December 13, 2009 - 12:12pm
Source:
Medical News Today
News Tags:
schizophrenia
Headline:
Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia
Do Not Allow Advertisers to Use My Personal information
